Press Releases Archives

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress

-- Researchers Shared Findings Including a Clinically Manageable Safety Profile and Anti-leukemic Activity with WU-CART-007 in Patients with R/R T-ALL/LBL and Previously Treated with Existing Therapies -- -- U.S. Biotech…

14 June

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

-- Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for this Investigational, Off-the-Shelf Allogeneic CAR-T Cell Therapy -- -- Company…

20 May

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies

The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / - Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage…

14 March

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers ROCKVILLE, MD, and ST LOUIS, MO, January 30, 2024 — MaxCyte,…

30 January

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer

-- Dr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the Role --ST. LOUIS, MO and SAN DIEGO, CA, Jan. 3, 2024 – Wugen,Inc., a clinical-stage…

03 January

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

-- Positive trends continue as more patients receive treatment with WU-CART-007 in this study exploring the drug’s potential in improving standard of care ---- WU-CART-007 continues to demonstrate favorable tolerability…

11 December

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in Hard-to-Treat T-ALL/LBL Patients ---- Results from…

02 November

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML — — Wugen Earns FDA Orphan Drug Designation for WU-NK-101 for…

15 August

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- -- WU-CART-007 demonstrated preliminary evidence of anti-leukemic activity; achieved 57%…

09 June

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

-- First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with R/R T-ALL/LBL -- -- Additional clinical data showcase the…

11 May

ARCHIVE

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

ST. LOUIS

SAN DIEGO

SOCIAL